FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
The 8,200-store chain would expand to 11,000 locations operating in 10 countries, if shareholders approve.
The agreement between AbbVie and Express Scripts is seen as a seismic shift in the joint development of cost-effective therapies, and gives the new regimen a slight edge on Gilead's popular remedies.
The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
"The trouble is that the market is changing much faster than most marketers realize."
Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.
The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.